Ivana Micallef
Overview
Explore the profile of Ivana Micallef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tun A, Wang Y, Maliske S, Micallef I, Inwards D, Habermann T, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):1001.e1-1001.e12.
PMID: 38996973
The standard of care (SOC) for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) ≥12 months after completing frontline therapy is salvage chemotherapy (ST) followed by autologous stem cell...
2.
Tun A, Wang Y, Maliske S, Micallef I, Inwards D, Habermann T, et al.
Haematologica
. 2024 Jan;
109(7):2186-2195.
PMID: 38235513
Chimeric antigen receptor T-cell therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a...
3.
Desai S, Spinner M, Evens A, Sykorova A, Bachanova V, Goyal G, et al.
Blood Adv
. 2023 Sep;
7(23):7295-7303.
PMID: 37729621
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3...
4.
Crees Z, Rettig M, Jayasinghe R, Stockerl-Goldstein K, Larson S, Arpad I, et al.
Nat Med
. 2023 Apr;
29(4):869-879.
PMID: 37069359
Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect optimal CD34 hematopoietic stem and progenitor cell (HSPC) numbers with granulocyte...
5.
Tun A, Wang Y, Matin A, Inwards D, Habermann T, Micallef I, et al.
Hemasphere
. 2023 Apr;
7(4):e869.
PMID: 37034004
Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse,...
6.
McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):371-377.
PMID: 36416595
Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement...
7.
Tun A, Maliske S, Wang Y, Inwards D, Habermann T, Micallef I, et al.
Transplant Cell Ther
. 2022 Jun;
28(9):610-617.
PMID: 35752441
Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who achieve progression-free survival (PFS) at 24 months (PFS24) after immunochemotherapy (IC) have excellent overall survival (OS) comparable to that of...
8.
Kuhlman J, Alhaj Moustafa M, Jiang L, Iqbal M, Seegobin K, Wolcott Z, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):e815-e825.
PMID: 35534379
Introduction: Leukemic involvement in high grade B cell lymphoma (L-HGBL) is rare and has been sparsely described in the literature. We report our experience in a large single institution multicenter...
9.
Desai S, Pederson L, Laplant B, Mwangi R, Maurer M, Young J, et al.
Blood Cancer J
. 2022 May;
12(5):78.
PMID: 35504884
Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and have conflicting...
10.
Iqbal M, Gil Castano Y, Paludo J, Rosenthal A, Li Z, Beltran M, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(2):e89-e95.
PMID: 34593359
Germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) at diagnosis is associated with superior long-term outcomes compared to non-GCB-DLBCL in patients treated with conventional chemo-immunotherapy. Whether cell of origin...